Medicament for slowing down angiogenesis of eye section

A new blood vessel and drug technology, applied in the field of preparations for inhibiting the development of AMD-related damage, can solve problems such as the inability to effectively regress new blood vessels

Inactive Publication Date: 2009-01-21
TIANJIN PHARMA GROUP CORP
View PDF5 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Steroids alone can somewhat reduce neovascularization, bu

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for slowing down angiogenesis of eye section
  • Medicament for slowing down angiogenesis of eye section
  • Medicament for slowing down angiogenesis of eye section

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Main ingredients: Pregna-1,4,9(11)-triene-3,20-diketone-17,21-dihydroxy-6α-methyl-21-acetate 10.0g

[0045] (Particle size 5~20μm)

[0046] Accessories:

[0047] Sodium Carboxymethyl Cellulose 2.0g

[0048] Tween-80 0.8g

[0049] Sodium dihydrogen phosphate 4.35g

[0050] Disodium hydrogen phosphate 6.75g

[0051] Sodium chloride 4.0g

[0052] Ethylparaben 0.1g

[0053] Propylparaben 0.1g

[0054] Water for injection 1000ml

[0055] Dissolve the prescribed amount of ethylparaben and propylparaben in water for injection with 50% of the prescribed amount, heat to 80-90°C, add the prescribed amount of Tween-80, sodium dihydrogen phosphate, dihydrogen phosphate Dissolve sodium and sodium chloride, filter with No. 3 vertical melting funnel, and use as solution, dissolve sodium carboxymethylcellulose in water for injection with 30% prescription volume, and use a cloth with a 200-mesh nylon cloth Filter through a funnel, heat to 80-90°C, add the...

Embodiment 2

[0057] The main ingredient is pregna-1,4,9(11)-triene-3,20-diketone-17,21-dihydroxy-21-propionate, and the formulation and preparation method of the auxiliary materials are the same as in Example 1.

Embodiment 3

[0059] The main ingredient is pregna-1,4,9(11)-triene-3,20-diketone-17,21-dihydroxy-21-acetate-16α-methyl, and the formula and preparation method of the auxiliary materials are the same as in the examples 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a steroid compound to a medicine for inhibiting the generation of ocular neovascularization. The preparation of preparations related to the medicine is also related.

Description

[0001] The present invention relates to the application of a steroid compound (I) in medicine for inhibiting ocular neovascularization. The invention relates to the preparation of the drug-related preparation. Background of the invention [0002] Various drugs are known to inhibit the formation of new blood vessels (angiogenesis or neovascularization). For example, in "A New Class of steroids Inhibits Angiogenesis in the Presence Of Heparin or a Heparin Fragment, Science, Vol.230: 1375- 1378, December 20, 1985) discloses steroids that inhibit angiogenesis in the presence of heparin or specific heparin fragments. The authors refer to such steroids as "angiostatic" steroids. Included in this class of steroids found to have vasopressive effects are the dihydro and tetrahydro metabolites of cortisone and predoxycortisone. In a follow-up study to test the hypothesis about the mechanism, it was demonstrated that the heparin / angiostatic steroid combination causes dissolution of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/573A61P27/02
Inventor 卢彦昌孙亮杨新意
Owner TIANJIN PHARMA GROUP CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap